Feb 21 (Reuters) - bluebird bio Inc BLUE.O:
BLUEBIRD BIO ANNOUNCES DEFINITIVE AGREEMENT TO BE ACQUIRED BY CARLYLE AND SK CAPITAL
BLUEBIRD BIO INC - STOCKHOLDERS TO RECEIVE $3.00 PER SHARE IN CASH
BLUEBIRD BIO INC - DAVID MEEK EXPECTED TO BECOME CEO OF BLUEBIRD UPON CLOSING OF DEAL
BLUEBIRD BIO INC - STOCKHOLDERS TO RECEIVE CONTINGENT VALUE RIGHT OF $6.84 PER SHARE FROM DEAL
BLUEBIRD BIO: ENTERED INTO AMENDMENTS TO LOAN AGREEMENT WITH HERCULES CAPITAL TO FACILITATE ADEQUATE LIQUIDITY
Source text: ID:nBwb7M3fsa
Further company coverage: BLUE.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.